Aspira Women's Health Q1 revenue up 26% to $2.3M; OvaSuite volume +29%

Aspira Women's Health Inc.

2023-Q1 EPS reported -$0.73 revenue$2,316,000

Product revenue $2.3M (+26% YoY); OvaSuite volume 6,259 units (+29% YoY).
Cash used in operations $5.7M, down 44% from $10.2M YoY; total cash $7.5M at Mar 31.
Gross margin 51.4% vs 50.8%; revenue per test $370 (-2%).
2H 2023 milestones: OvaWatch serial monitoring test study completion, EndoCheck launch.
Board approved 1-for-15 reverse stock split; secured up to $22.5M in capital facilities.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aspira Women's Health Inc. reported the three months ended March 31, 2023 results: revenue $2.3 million. Guidance reaffirmed.

Period: the three months ended March 31, 2023
Revenue: $2.3 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

regardless of any incorporation by reference language in such filing. --- EX-99.1 (EX-99.1) --- 2023-05-11 8K Ex 991 Exhibit 99 .1 First Quarter total product revenue of $2.3 million, an increase of 26% year-over-year First Quarter OvaSuite volume of 6,259 units, an increase of 29% year-over-year First Quarter cash used in operations of $5.7 million, a

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

Aspira Women's Health Inc. filing history →

Source: SEC EDGAR

accession 0000926617-23-000039

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.